



IAP07Rec'd PCT 03 MAR 2008

PCT/A

Atty. Dkt. No. 023312-0120

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hiroshi TAKAYAMA et al.
Title: ANTI-PLATELET MEMBRANE
GLYCOPROTEIN VI
MONOCLONAL ANTIBODY
(As Amended)

Appl. No.: 10/564,745

International 7/20/2004

Filing Date:

371(c) Date: 5/11/06

Examiner: Michael E. SZPERKA

Art Unit: 1644

Confirmation 1476
Number:

AMENDMENT TRANSMITTAL

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an amendment in the above-identified application.

☐ Small Entity status under 37 C.F.R. § 1.9 and § 1.27 has been established by a previous assertion of Small Entity status.

☐ Assertion of Small Entity status is enclosed.

☒ The fee required for additional claims is calculated below:

	Claims As Amended		Previously Paid For		Extra Claims Present		Rate		Additional Claims Fee
Total Claims:	11	-	20	=	0	x	\$50.00	=	\$0.00
Independent Claims:	7	-	6	=	1	x	\$210.00	=	\$210.00
First presentation of any Multiple Dependent Claims: + \$0.00 =									\$0.00
CLAIMS FEE TOTAL =									\$210.00

☐ Applicant hereby petitions for an extension of time under 37 C.F.R. §1.136(a) for the total number of months checked below:

<input type="checkbox"/> Extension for response filed within the first month:	\$120.00	\$0.00
<input type="checkbox"/> Extension for response filed within the second month:	\$460.00	\$0.00
<input type="checkbox"/> Extension for response filed within the third month:	\$1,050.00	\$0.00
<input type="checkbox"/> Extension for response filed within the fourth month:	\$1,640.00	\$0.00
<input type="checkbox"/> Extension for response filed within the fifth month:	\$2,230.00	\$0.00
EXTENSION FEE TOTAL:		\$0.00
<input type="checkbox"/> Statutory Disclaimer Fee under 37 C.F.R. 1.20(d):	\$130.00	\$0.00
CLAIMS, EXTENSION AND DISCLAIMER FEE TOTAL:		\$210.00
<input type="checkbox"/> Small Entity Fees Apply (subtract ½ of above):		\$0.00
Extension Fees Previously Paid:		\$0.00
TOTAL FEE:		\$210.00

03/12/2008 GFREY1 00000001 190741 10564745

01 FC:1614 210.00 DA

A credit card payment form in the amount of \$210.00 is enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit card payment form being unsigned, providing incorrect information resulting in a

03/05/2008 GFREY1 00000038 10564745

01 FC:2617 65.00 OP

WASH_2991653.1

The PTO did not receive the following listed item(s) Credit Card for
\$210.00

rejected credit card transaction, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

If any extensions of time are needed for timely acceptance of papers submitted herewith, applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date March 3, 2008

By 

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

Stephen B. Maebius
Attorney for Applicant
Registration No. 35,264



Atty. Dkt. No. 023312-0120

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hiroshi TAKAYAMA et al.
Title: ANTI-PLATELET MEMBRANE
GLYCOPROTEIN VI
MONOCLONAL ANTIBODY
Appl. No.: 10/564,745
International Filing Date: 7/20/2004
371(c) Date: 5/11/06
Examiner: Michael E. SZPERKA
Art Unit: 1644
Confirmation Number: 1476

RESPONSE TO RESTRICTION REQUIREMENT
AND AMENDMENT UNDER 37 CFR § 1.111

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the restriction requirement set forth in the Office Action mailed February 01, 2008, Applicant hereby provisionally elects Group I, Claims 1-5 and 8, for examination, without traverse. Applicants additionally submit amended claims 1-4 and new claims 10-11.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this document.